Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE versus IQUIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE versus IQUIX.
CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE vs IQUIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
Otic suspension: 3 drops (0.25 mL) into affected ear(s) twice daily for 7 days. Each drop contains ciprofloxacin HCl (equivalent to 0.2 mg ciprofloxacin base) and hydrocortisone 1 mg.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
None Documented
None Documented
Ciprofloxacin: ~4-5 hours (normal renal function); prolonged to 8-10 hours in severe renal impairment (CrCl <30 mL/min). Hydrocortisone: ~1.5-2 hours.
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Ciprofloxacin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; ~15-20% as metabolites; ~20-30% in feces via biliary excretion and transintestinal secretion. Hydrocortisone: metabolized in liver, metabolites excreted renally.
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic